Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
701 to 720 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait? | Eur J Haematol | 2022 | 35030282 | PubTator, text mining | PubMed |
| First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. | Haematologica | 2022 | 35021599 | PubTator, text mining | PubMed |
| Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. | Nature | 2022 | 35016194 | PubTator, text mining | PubMed |
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. | Leuk Lymphoma | 2022 | 35014928 | PubTator, text mining | PubMed |
| Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions. | Nat Commun | 2022 | 35013316 | PubTator, text mining | PubMed |
| The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. | Blood Adv | 2022 | 35008098 | PubTator, text mining | PubMed |
| Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. | Am J Hematol | 2022 | 34989420 | PubTator, text mining | PubMed |
| Inside the chronic lymphocytic leukemia cell: miRNA and chromosomal aberrations. | Mol Med Rep | 2022 | 34981813 | PubTator, text mining | PubMed |
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. | Leukemia | 2022 | 34974526 | PubTator, text mining | PubMed |
| Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i. | Blood Adv | 2022 | 34965297 | PubTator, text mining | PubMed |
| Is a BTKi or BCL2i preferable for first "novel" therapy in CLL? The case for BTKis. | Blood Adv | 2022 | 34965291 | PubTator, text mining | PubMed |
| Loss-of-function SLC30A2 mutants are associated with gut dysbiosis and alterations in intestinal gene expression in preterm infants. | Gut Microbes | 2022 | 34965180 | PubTator, text mining | PubMed |
| SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. | Leukemia | 2022 | 34937858 | PubTator, text mining | PubMed |
| Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy. | Drugs | 2022 | 34932207 | PubTator, text mining | PubMed |
| Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. | Br J Haematol | 2022 | 34915592 | PubTator, text mining | PubMed |
| Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features. | Target Oncol | 2022 | 34905129 | PubTator, text mining | PubMed |
| Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. | J Clin Invest | 2022 | 34882582 | PubTator, text mining | PubMed |
| Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. | Br J Haematol | 2022 | 34865212 | PubTator, text mining | PubMed |
| Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies. | Mol Oncol | 2022 | 34861096 | PubTator, text mining | PubMed |
| Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. | Blood | 2022 | 34861036 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=36